Introduction
Mammary gland carcinomas are a very common malignancy in adult bitches. 1 In dogs, approximately 50% of mammary gland tumors are malignant, and 50% of these tend to infiltrate the surrounding tissues and metastasize to regional lymph nodes and lungs. 1, 2 Furthermore, different histological subtypes can be frequently found in different mammary glands, some of which correlate with clinical behavior. 1, 3 Surgical excision is the main treatment option for mammary gland tumors; 1, 3 however, aggressive tumors are rarely cured by surgery alone, and affected dogs may ultimately die or be euthanized because of distant metastases. [4] [5] [6] Due to the poor outcome in many dogs, adjuvant treatments are clearly warranted. Chemotherapy has been rarely attempted in dogs with aggressive malignant mammary tumors and scarce data has been published on postoperative adjuvant treatments. 7, 8 At present, a standard of care for adjuvant chemotherapy has not been established.
In human patients with breast cancer, mastectomy alone is often disappointing. Thus, adjuvant systemic therapy following local treatment is used in order to eradicate micrometastases and ameliorate disease-free interval and overall survival. 9 Currently, adjuvant chemotherapy is offered to patients with node-positive tumors or with highgrade tumors and to those with metastatic disease. [10] [11] [12] Chemotherapeutic drugs that have shown efficacy in the management of breast cancer include anthracyclines (such as doxorubicin or epirubicin), [13] [14] [15] [16] taxanes (such as paclitaxel or docetaxel), [17] [18] [19] and the newly introduced vinorelbine, 20 capecitabine, 20, 21 and gemcitabine [22] [23] [24] [25] in both pretreated and unpretreated patients, either as single agents or in combination regimens. In particular, gemcitabine, a pyrimidine nucleoside antimetabolite, has emerged as one of the most promising new cytotoxic agents, because of its proven antitumor activity in a variety of solid tumors, its good toxicity profile and no apparent multidrug resistance. 26 Gemcitabine is not widely used in veterinary medicine, and few articles are available in the literature. [27] [28] [29] [30] [31] To the authors' knowledge, adjuvant gemcitabine chemotherapy for resected mammary cancer care has not been documented in dogs. The aims of the study were i) to verify the potential beneficial effects of gemcitabine and surgery over surgery alone on time to local recurrence (TTR), time to distant metastases (TTM) and overall survival (OS) in dogs with mammary carcinoma; ii) to assess factors contributing to OS in either group of dogs; and iii) to assess the safety of gemcitabine administration and quality of life in dogs receiving adjuvant chemotherapy.
Materials and methods

Patient eligibility
Following radical unilateral or bilateral mastectomy, depending on tumor distribution in the mammary chains, canine patients were eligible for recruitment only if they had selected malignant histological variants, including simple carcinoma, squamous cell carcinoma, sarcoma and carcinosarcoma with infiltrative growth in the stroma and residual neoplastic cells at the primary surgical site. Inflammatory mammary carcinoma was excluded. In addition, to be included in the study, dogs with mammary tumors had to exhibit one or more of the listed features: (1) vascular and/or lymphatic invasion, (2) metastases to regional lymph nodes, and (3) distant metastases. In cases of multiple mammary tumors, the most malignant tumor was considered. All dogs were staged accordingly to the WHO clinical staging system for canine mammary tumors. 1 For dogs undergoing chemotherapy, additional entry requirements included fully informed, written consent from the pet owner, the presence of adequate bone marrow function, as evidenced by neutrophil counts of ≥3.000/μl, platelet counts of ≥120.000/μl, and packed cell volume ≥30%, and administration of at least 4 doses of gemcitabine. Dogs were enrolled irrespective of hormone receptor status. Dogs affected by coexistent nonmammary malignancies, and those which had received previous chemotherapy or hormonal therapy were not enrolled.
Post-operative chemotherapy was offered to all dogs. If owners rejected adjuvant treatment, dogs were included in Group 1. Dogs whose owners wished to pursue chemotherapy were included in Group 2.
Pre-treatment evaluation
Before entering the study, all patients underwent staging work-up including a complete history and physical examination, bidimensional measurement of the tumors, cytologic evaluation of the mammary tumor and of regional lymph nodes, complete blood cell count (CBC), serum biochemical profile, urinalysis, abdominal ultrasound, and thoracic radiographs (right and left lateral, and ventrodorsal views).
Radical unilateral mastectomy was performed if only one mammary chain was involved, and bilateral mastectomy if either mammary chain was involved. For staging purposes, regional lymphadenectomy was performed in all dogs.
Histological assessment
Tissue samples were routinely fixed in 10% neutral buffered formalin and embedded in paraffin. Five-micron sections were taken, stained with hematoxylin and eosin (H&E) and examined by ligth microscopy. Histological assessment of mammary tumors and draining lymph nodes was performed by two independent pathologists (FA, AR) according to the World Health Organization's (WHO) classification scheme 32 . The following data were recorded: histological diagnosis, status of the resection margins, presence of stromal infiltration, vascular-lymphatic invasion, and grade of the tumor determined on the basis of previously described guidelines. 5 Hormone receptor status was not evaluated.
Post-operative chemotherapy plan
Patients were scheduled to start chemotherapy one week after mastectomy. Gemcitabine . If treatment had to be delayed, the CBC was repeated every 2 days in order to resume chemotherapy as soon as possible. A new cycle at full dose was only started if neutrophils were >3.000/μl, platelet count was >120.000/μl, and the non-hematologic toxicity grade was ≤1. Doselimiting toxicity was defined as grade 3 or 4 hematologic or gastrointestinal toxicity.
The safety analysis was performed on data from all patients who received gemcitabine.
Follow-up
After surgical excision (Group 1) or completion of chemotherapy (Group 2), dogs were scheduled to be checked once monthly for three months, and every three months thereafter. Follow-up examination included physical examination with particular attention to local recurrence, CBC, serum biochemical profile, abdominal ultrasound, and thoracic radiographs (three views).
Statistical analysis
Data analysis was performed with GraphPad Prism version 4.0 (GraphPad Software, San Diego, CA). For both groups, survival time, TTM (beyond regional lymph nodes),
and TTR were explored with the Kaplan-Meier product limit method followed by logrank test. In either group, timing was considered from surgical excision. In the analysis of survival, distant metastasis and local recurrence, dogs were censored if they were alive at the time of data accrual closure. For time to distant metastases and local recurrence dogs were also censored if, by the last examination, distant metastases had not developed or the tumor had not reappeared locally, respectively. In the two groups, the following variables were evaluated for their influence on survival time: neutering status, body weight, age, clinical stage at presentation, tumor size at surgery (measured at its maximum diameter), histological grade and, in dogs receiving chemotherapy, the number of gemcitabine treatments. Correlations were not investigated for TTM and TTR because of the low number of dogs which developed metastasis or local recurrence available for analysis. Spearman's correlation coefficient was used to measure the strength of relationships. Significance was set at a p value of ≤0.05.
Results
Patient characteristics
Nineteen dogs with histologically confirmed malignant mammary gland tumors were enrolled. Among these, 9 dogs were treated with surgery alone (Group 1), whereas the remaining 10 received post-operative adjuvant gemcitabine (Group 2). All patients were treated at the Clinica Veterinaria L'Arca between October 2003 and October 2006.
In Group 1, 6 breeds were represented, including crossbreeds (n=4), and one each of the following: shi-tzu, German shepherd, German pointer, poodle, and Yorkshire terrier.
Median age at presentation was 12 years (range, [8] [9] [10] [11] [12] [13] [14] [15] , and median body weight was bitches had metastatic disease at presentation, and 2 of these had pulmonary involvement.
Group 2
In this group, the median number of tumors per dog was 2 (range, 1-6) and the median size of the major tumor nodule at its maximum diameter was 3.7 cm (range, 1.7-6).
Concerning histological type, 8 bitches (80%) had simple carcinoma, 3 of which were anaplastic, 2 were solid, 2 were tubulopapillary and one was tubular. In addition, there was one carcinosarcoma and one adenosquamous carcinoma. The tumors were histologically graded as follows: 6 tumors (60%) were grade 2, and 4 tumors (40%)
were grade 3. Histologic evidence of residual tumor at the primary surgical site was noted in all dogs.
At diagnosis, 6 dogs (60%) had stage IV disease and 4 (40%) had stage V. The metastatic site in the dogs with stage V disease was the lungs, whereas the histologically involved lymph nodes were the inguinal in 7 dogs, the axillary in one dog, and both, the inguinal and the axillary, in one dog. Overall, all 10 dogs had metastatic disease at the beginning of gemcitabine chemotherapy, and 4 of these had pulmonary involvement.
Chemotherapy
Chemotherapy was started between 7 and 14 days after mastectomy in 10 dogs. A total of 61 gemcitabine treatments were administered at the dose of 800 mg/m 2 . Dogs received from 4 to 10 gemcitabine treatments (median, 6.1). All patients completed the planned four cycles of chemotherapy, and 7 of them (70%) received 1-6 additional treatments.
Response and time-to-event measures
The median follow-up time (from surgery to last visit) was 178 days (range, and 203 days (range, 52-659) for Group 1 and 2, respectively.
Overall, 4 (44.4%) out of 9 dogs with no postoperative gemcitabine developed local recurrence (Group 1). Median time to local recurrence was 175 days (range, 150-345).
None of the 10 dogs that received adjuvant chemotherapy developed local recurrence (Group 2). Time to local recurrence was not different between groups.
In Group 1, 4 dogs had distant metastases. In particular, 2 dogs showed pulmonary metastases at presentation, and 2 others developed pulmonary metastases after 212 and Results of treatments for Group 1 and 2 are summarized in Table 1 and Table 2, respectively.
Regarding factors associated with OS, a significantly positive correlation was documented for the number of gemcitabine treatments in dogs receiving adjuvant chemotherapy (p=0.017). No correlations were found for other analyzed variables.
Toxicity
All 10 patients receiving gemcitabine chemotherapy were evaluated for toxicity.
Treatment was well tolerated and no dose reduction was necessary during the study period. No dog required treatment interruption. Most of the treatments (57 of 61, 93%)
were administered every week, as planned. In 4 cases treatment delays were necessary due to grade 1 neutropenia, which resolved uneventfully after 3, 4, 4 and 5 days, respectively, by adding oral 5 mg kg -1 SID enrofloxacin (Baytril tablets 150 mg, Bayer, Milan, Italy) for one week with no need for hospitalization. All treatment delays occurred after the first 4 courses of chemotherapy. Grade 2 to grade 4 hematologic toxicity was not reported during the study.
Non-hematologic toxicity occurred in very rare cases and was limited to grade 1-2 gastrointestinal adverse events. One dog experienced nausea without alteration in eating habits for 24 hours after each cycle, whereas another dog had one episode of loss of appetite of 36 hours duration and 3-5 episodes of vomiting in 48 hours. Further nonhematologic toxicities were not observed during the study. Chemotherapy did not affect wound healing in any case.
Discussion
Much interest has focused on the treatment of mammary carcinoma in dogs. Until recently, mammary carcinoma in bitches was viewed as a surgical issue and no medical treatment was recommended. 1, 3 However, approximately 50% of mammary tumors behave aggressively and will ultimately locally recur and progress to metastatic disease, suggesting that occult metastases are already present when dogs first present with operable mammary cancer. Recently, the use of adjuvant chemotherapy for the treatment of resected canine mammary tumors has been reported. 7, 8 In an early study, 8 bitches with malignant mammary tumors were treated in an adjuvant post-operative setting with 5-fluorouracil and cyclophosphamide. 7 When compared with bitches treated by surgery alone, the authors found a benefit in survival time if chemotherapy was added. 7 More recently, 12
dogs with invasive mammary gland tumors were treated with doxorubicin or docetaxel after mastectomy; however, outcome was not improved by chemotherapy. 8 In people, gemcitabine has shown activity in a variety of solid tumors, [35] [36] [37] [38] [39] has limited toxicity, and does not exacerbate toxic effects of other chemotherapeutic drugs. 40 Moreover, among the novel chemotherapeutic drugs, gemcitabine has emerged as an important agent in the treatment of breast cancer in women. 22, 24, 26, [41] [42] [43] [44] The efficacy and tolerability of this chemotherapeutic drug, as well as its lack of cross-resistance with anthracyclines and taxanes, have led to its inclusion in combination regimens. [45] [46] [47] [48] Motivated by the favorable results in humans with aggressive breast cancer, and the good tolerability shown in canine patients, 33 we designed a clinical protocol with gemcitabine given as a single agent to dogs with aggressive mammary cancer. In the present study, the analysis of post-operative adjuvant therapy with gemcitabine showed prolongation of the recurrence-free survival over no adjuvant chemotherapy. In Limitations of this study are the low number of recruited patients in both groups, partly due to the strict enrolment criteria and the relatively short follow-up achieved in some dogs. We hypothesize that the patient number was too low to detect statistical differences among groups, and that longer follow-up would be necessary to better understand the potential beneficial effects of gemcitabine on survival time and time to occurrence of metastases.
Several clinico-pathological prognostic factors have been identified for canine mammary tumors. 5, [50] [51] [52] [53] In the present study, several variables were evaluated for their prognostic influence, and the analysis indicated that clinical stage at diagnosis had a statistically significant negative influence on the survival rates of dogs treated by surgery alone. This finding is in agreement with previously reported data. 53, 54 The number of gemcitabine treatments had a significant positive influence on survival time of treated dogs in this study. However, this finding needs to be interpreted with caution, as it may be explained by the fact that dogs living longer received additional cycles of gemcitabine. None of the other analyzed variables proved to be associated in the present canine population, probably due to the low number of enrolled dogs and to the aggressive nature of the tumor in the selected animals.
In this study high-dose gemcitabine treatment was well tolerated with a low incidence of adverse events. Quality of life was maintained, if not improved in all treated dogs, especially in those presenting with respiratory signs. The planned timing of chemotherapy was respected for most of the cycles and only 4 treatments were delayed as a result of grade 1 neutropenia. In these 4 dogs, neutropenic episodes were uncomplicated and rapidly reversible, and hospitalization was not necessary. It may be possible that prophylactic antibiotic therapy given to all dogs during the first 3 weeks of treatment prevented infection-related events and attendant chemotherapy delays and dose reductions. Moreover, in this study non-hematologic toxicity was very mild and was observed in two dogs only. No grade 2-4 hematologic and grade 3-4 nonhematologic toxicity was observed, and no treatment-related deaths occurred. These findings have important implications, not only for the feasibility of gemcitabine in the adjuvant setting, but also for its potential use in combination regimens.
In conclusion, there are still many unanswered questions about the absolute benefit of adjuvant chemotherapy in canine mammary tumor care, and further studies are needed to better understand the role of gemcitabine and to substantiate its use. In human patients, combination regimens are generally superior to single agents in terms of response rate, duration of response and survival. Indeed, as single agent, gemcitabine yields response rates ranging from 16% to 37%; whereas, if combined with other chemotherapeutic drugs, response rates rise to 50% to 80%. [40] [41] [42] [43] [44] [45] [46] [47] [48] Given these data, future veterinary clinical trials in dogs with resected aggressive mammary carcinoma should focus on the adjuvant role of gemcitabine alone or in combination with other chemotherapeutic drugs.
